Discover how Chroma is expanding our impact.

Boston, MA., September 21, 2023 — Chroma Medicine, Inc. (Chroma), a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced it was named to the Endpoints 11 2023 list of the most promising biotechs by Endpoints News. This annual award celebrates companies with leading-edge science that are pioneering the development of new medicines. Building on groundbreaking research from the world’s foremost genomic medicine experts, Chroma is rapidly advancing a new class of therapeutics that harness epigenetics, nature’s innate mechanism for gene regulation, to achieve unparalleled control of gene expression without cutting, nicking, or altering the DNA sequence. After securing…

Boston, MA, September 20, 2023 – Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today presented positive preclinical data demonstrating the potential of its epigenetic editors to produce efficacious, specific, and durable silencing of the hepatitis B virus (HBV) during the HBV International Meeting 2023, held September 19-23 in Kobe, Japan. Chronic hepatitis B is incurable, increases the risk of developing liver cirrhosis and hepatocellular cancer, and impacts nearly 300 million people worldwide, accounting for more than 800,000 deaths per year. Antiviral therapy can suppress viral replication, but requires lifelong dosing and few patients achieve…

Brisbane, California, and Boston, Massachusetts, JULY 20, 2023 – Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a clinical-stage genomic medicine company and Chroma Medicine, Inc. (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced they have entered into a research evaluation, option and license agreement to develop epigenetic medicines leveraging zinc finger proteins (ZFPs) for sequence-specific DNA recognition. Over the course of two decades, Sangamo has built and validated the world’s largest library of ZFPs, deploying them to address numerous therapeutically relevant targets.  Advancing the transformative potential of epigenetic editing, Chroma is expanding the versatility of its platform by…

Boston, MA, May 19, 2023 – Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today presented data demonstrating the advantages of epigenetic editing for multiplex gene regulation at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting in Los Angeles. Chroma’s epigenetic editing platform harnesses the cell’s endogenous mechanism for regulating gene expression to durably modulate transcription without cutting or nicking the DNA, offering a potentially safer approach for multiplex editing. This avoids challenges associated with gene editing methods that rely upon DNA breaks to alter gene expression, which have the potential…